Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 101.1.C.003 | Other Identifier | Optimerpharma Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).
The primary objective of this pivotal study is to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD). The cure rates at end of therapy and recurrence rates will be evaluated and compared.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| fidaxomicin | Experimental | Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours [q12h] regimen) with intermittent matching placebo to fidaxomicin |
|
| Vancomycin | Active Comparator | Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours [q6h] regimen). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fidaxomicin | Drug | 200 mg oral capsules two times daily (q12h regimen) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cure Rate at End of Therapy | Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication. | Study day 10 (+/- 2 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence | Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. | Study days 11-40 |
| Measure | Description | Time Frame |
|---|---|---|
| Global Cure | Percentage of participants who were cured (3 or fewer unformed stools for 2 days through the end of therapy, and no C. difficile therapy after study drug completion) and didn't have recurrence (re-establishment of diarrhea that was greater than on the last day of study drug, positive C. difficile toxin and retreatment with C. difficile therapy) up to Day 40. | End of Study (Day 40) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21288078 | Result | Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812. | |
| 24599770 | Derived | D'Agostino RB Sr, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis. 2014 May;58(10):1386-93. doi: 10.1093/cid/ciu107. Epub 2014 Mar 5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Subjects were enrolled from May 2006 to August 2008 by centers in the United States and Canada.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Vancomycin | 125 mg administered 4 times daily (q6hr) |
| FG001 | Fidaxomicin | 200 mg administered twice daily (q12hr) |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Enrollment |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Vancomycin | Drug | 125 mg capsules q6hr (4 times a day) |
|
| Matching Placebo to Fidaxomicin | Drug | Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing) |
|
| 23715579 | Derived | Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013 Jul 1;31(19):2493-9. doi: 10.1200/JCO.2012.45.5899. Epub 2013 May 28. |
| 22752865 | Derived | Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S154-61. doi: 10.1093/cid/cis462. |
| 22752862 | Derived | Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S132-42. doi: 10.1093/cid/cis338. |
| 22752860 | Derived | Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S121-6. doi: 10.1093/cid/cis440. |
| 22752857 | Derived | Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S104-9. doi: 10.1093/cid/cis357. |
| COMPLETED |
|
| NOT COMPLETED |
|
| Treatment |
|
|
| Follow-up |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Vancomycin | 125 mg administered 4 times daily (q6hr) |
| BG001 | Fidaxomicin | 200 mg administered twice daily (q12hr) |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cure Rate at End of Therapy | Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication. | Analysis data is modified intent to treat (mITT) population. The mITT population consists of subjects that had CDAD confirmed by >3 unformed bowel movements in the 24 hours prior to randomization and a positive toxin assay and received at least one dose of study medication. | Posted | Number | 95% Confidence Interval | Percentage of Participants | Study day 10 (+/- 2 days) |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Recurrence | Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. | The mITT population for subjects who met the primary endpoint of cure subjects, were analyzed for the recurrence rates of diarrhea up to the Poststudy Visit. | Posted | Number | Percentage of Participants | Study days 11-40 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Global Cure | Percentage of participants who were cured (3 or fewer unformed stools for 2 days through the end of therapy, and no C. difficile therapy after study drug completion) and didn't have recurrence (re-establishment of diarrhea that was greater than on the last day of study drug, positive C. difficile toxin and retreatment with C. difficile therapy) up to Day 40. | The analysis population is mITT, subjects that achieved a cure response at end of treatment and not having a recurrence at any time up to the Post-study visit. | Posted | Number | Percentage of Participants | End of Study (Day 40) |
|
|
From Informed consent to 7-days following the last dose of study drug or until the last protocol-specified study visit, whichever occured later.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Vancomycin | 125 mg administered 4 times daily (q6hr) | 78 | 323 | 195 | 323 | ||
| EG001 | Fidaxomicin | 200 mg administered twice daily (q12hr) | 75 | 300 | 187 | 300 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Anaemia | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Granulocytopenia | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Leukocytosis | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Leukopenia | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Lymphadenopathy | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Lymphopenia | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Cardiac failure congestive | Cardiac disorders | MedDRA 10.0 |
| ||
| Cardiogenic shock | Cardiac disorders | MedDRA 10.0 |
| ||
| Myocardial infarction | Cardiac disorders | MedDRA 10.0 |
| ||
| Atrial fibrillation | Cardiac disorders | MedDRA 10.0 |
| ||
| Atrial flutter | Cardiac disorders | MedDRA 10.0 |
| ||
| Cardiac arrest | Cardiac disorders | MedDRA 10.0 |
| ||
| Cor pulmonale | Cardiac disorders | MedDRA 10.0 |
| ||
| Supraventricular tachycardia | Cardiac disorders | MedDRA 10.0 |
| ||
| Ventricular tachycardia | Cardiac disorders | MedDRA 10.0 |
| ||
| Cleft palate | Congenital, familial and genetic disorders | MedDRA 10.0 |
| ||
| Diarrhoea | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Large intestine perforation | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Abdominal pain | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Ascites | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Colitis ischaemic | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Ileus | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Inguinal hernia, obstructive | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Peritonitis | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Colitis | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Intestinal obstruction | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Megacolon | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Small intestinal obstruction | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Vomiting | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Chest pain | General disorders | MedDRA 10.0 |
| ||
| Malaise | General disorders | MedDRA 10.0 |
| ||
| Pyrexia | General disorders | MedDRA 10.0 |
| ||
| Generalised oedema | General disorders | MedDRA 10.0 |
| ||
| Hypothermia | General disorders | MedDRA 10.0 |
| ||
| Impaired healing | General disorders | MedDRA 10.0 |
| ||
| Multi-organ failure | General disorders | MedDRA 10.0 |
| ||
| Oedema peripheral | General disorders | MedDRA 10.0 |
| ||
| Cholecystitis acute | Hepatobiliary disorders | MedDRA 10.0 |
| ||
| Cholelithiasis | Hepatobiliary disorders | MedDRA 10.0 |
| ||
| Liver disorder | Hepatobiliary disorders | MedDRA 10.0 |
| ||
| Anaphylactic reaction | Immune system disorders | MedDRA 10.0 |
| ||
| Clostridium difficile colitis | Infections and infestations | MedDRA 10.0 |
| ||
| Pneumonia | Infections and infestations | MedDRA 10.0 |
| ||
| Sepsis | Infections and infestations | MedDRA 10.0 |
| ||
| Staphylococcal bacteraemia | Infections and infestations | MedDRA 10.0 |
| ||
| Staphylococcal sepsis | Infections and infestations | MedDRA 10.0 |
| ||
| Urosepsis | Infections and infestations | MedDRA 10.0 |
| ||
| Aspergillosis | Infections and infestations | MedDRA 10.0 |
| ||
| Bacteraemia | Infections and infestations | MedDRA 10.0 |
| ||
| Endocarditis bacterial | Infections and infestations | MedDRA 10.0 |
| ||
| Enterocolitis infectious | Infections and infestations | MedDRA 10.0 |
| ||
| Escherichia bacteraemia | Infections and infestations | MedDRA 10.0 |
| ||
| Escherichia sepsis | Infections and infestations | MedDRA 10.0 |
| ||
| Meningitis | Infections and infestations | MedDRA 10.0 |
| ||
| Postoperative wound infection | Infections and infestations | MedDRA 10.0 |
| ||
| Pseudomonal sepsis | Infections and infestations | MedDRA 10.0 |
| ||
| Pyelocystitis | Infections and infestations | MedDRA 10.0 |
| ||
| Septic shock | Infections and infestations | MedDRA 10.0 |
| ||
| Systemic candida | Infections and infestations | MedDRA 10.0 |
| ||
| Wound infection staphylococcal | Infections and infestations | MedDRA 10.0 |
| ||
| Abdominal abscess | Infections and infestations | MedDRA 10.0 |
| ||
| Abdominal sepsis | Infections and infestations | MedDRA 10.0 |
| ||
| Cellulitis | Infections and infestations | MedDRA 10.0 |
| ||
| Fungaemia | Infections and infestations | MedDRA 10.0 |
| ||
| Pyelonephritis acute | Infections and infestations | MedDRA 10.0 |
| ||
| Sepsis syndrome | Infections and infestations | MedDRA 10.0 |
| ||
| Shunt infection | Infections and infestations | MedDRA 10.0 |
| ||
| Sinusitis | Infections and infestations | MedDRA 10.0 |
| ||
| Subcutaneous abscess | Infections and infestations | MedDRA 10.0 |
| ||
| Wound dehiscence | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Femur fracture | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Gastrointestinal anastomotic leak | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Graft haemorrhage | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Muscle strain | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Accidental overdose | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Hip fracture | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Vascular graft occlusion | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Blood glucose abnormal | Investigations | MedDRA 10.0 |
| ||
| Blood phosphorus decreased | Investigations | MedDRA 10.0 |
| ||
| Blood uric acid increased | Investigations | MedDRA 10.0 |
| ||
| Lymphocyte count decreased | Investigations | MedDRA 10.0 |
| ||
| White blood cell count decreased | Investigations | MedDRA 10.0 |
| ||
| Alanine aminotransferase increased | Investigations | MedDRA 10.0 |
| ||
| Aspartate aminotransferase increased | Investigations | MedDRA 10.0 |
| ||
| Blood calcium decreased | Investigations | MedDRA 10.0 |
| ||
| Blood calcium increased | Investigations | MedDRA 10.0 |
| ||
| Blood phosphorus abnormal | Investigations | MedDRA 10.0 |
| ||
| Blood sodium decreased | Investigations | MedDRA 10.0 |
| ||
| Blood urea abnormal | Investigations | MedDRA 10.0 |
| ||
| Blood uric acid abnormal | Investigations | MedDRA 10.0 |
| ||
| International normalised ratio increased | Investigations | MedDRA 10.0 |
| ||
| Liver function test abnormal | Investigations | MedDRA 10.0 |
| ||
| Neutrophil count decreased | Investigations | MedDRA 10.0 |
| ||
| Platelet count decreased | Investigations | MedDRA 10.0 |
| ||
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Dehydration | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hyperuricaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Failure to thrive | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Malnutrition | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Metabolic acidosis | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hypophosphataemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 10.0 |
| ||
| Endometrial cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.0 |
| ||
| Lung cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.0 |
| ||
| Acute myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.0 |
| ||
| Adrenal gland cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.0 |
| ||
| Lymphoproliferative disorder | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.0 |
| ||
| Renal cell carcinoma stage unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.0 |
| ||
| Coma | Nervous system disorders | MedDRA 10.0 |
| ||
| Syncope | Nervous system disorders | MedDRA 10.0 |
| ||
| Cerebrovascular accident | Nervous system disorders | MedDRA 10.0 |
| ||
| Convulsion | Nervous system disorders | MedDRA 10.0 |
| ||
| Intra-uterine death | Pregnancy, puerperium and perinatal conditions | MedDRA 10.0 |
| ||
| Pregnancy | Pregnancy, puerperium and perinatal conditions | MedDRA 10.0 |
| ||
| Mental status changes | Psychiatric disorders | MedDRA 10.0 |
| ||
| Confusional state | Psychiatric disorders | MedDRA 10.0 |
| ||
| Affective disorder | Psychiatric disorders | MedDRA 10.0 |
| ||
| Renal failure | Renal and urinary disorders | MedDRA 10.0 |
| ||
| Renal failure acute | Renal and urinary disorders | MedDRA 10.0 |
| ||
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Respiratory disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Haemopneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Deep vein thrombosis | Vascular disorders | MedDRA 10.0 |
| ||
| Haemorrhage | Vascular disorders | MedDRA 10.0 |
| ||
| Arterial occlusive disease | Vascular disorders | MedDRA 10.0 |
| ||
| Hypotension | Vascular disorders | MedDRA 10.0 |
| ||
| Vena cava thrombosis | Vascular disorders | MedDRA 10.0 |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 10.0 |
| ||
| Nausea | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Vomiting | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Diarrhoea | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Abdominal pain | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Constipation | Gastrointestinal disorders | MedDRA 10.0 |
| ||
| Oedema peripheral | General disorders | MedDRA 10.0 |
| ||
| Pyrexia | General disorders | MedDRA 10.0 |
| ||
| Chills | General disorders | MedDRA 10.0 |
| ||
| Fatigue | General disorders | MedDRA 10.0 |
| ||
| Pain | General disorders | MedDRA 10.0 |
| ||
| Urinary tract infection | Infections and infestations | MedDRA 10.0 |
| ||
| Pneumonia | Infections and infestations | MedDRA 10.0 |
| ||
| Fall | Injury, poisoning and procedural complications | MedDRA 10.0 |
| ||
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Dehydration | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 10.0 |
| ||
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 10.0 |
| ||
| Headache | Nervous system disorders | MedDRA 10.0 |
| ||
| Dizziness | Nervous system disorders | MedDRA 10.0 |
| ||
| Insomnia | Psychiatric disorders | MedDRA 10.0 |
| ||
| Renal failure acute | Renal and urinary disorders | MedDRA 10.0 |
| ||
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 |
| ||
| Rash | Skin and subcutaneous tissue disorders | MedDRA 10.0 |
| ||
| Hypotension | Vascular disorders | MedDRA 10.0 |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp. | 1-800-672-6372 | ClinicalTrialsDisclosure@merck.com |
| ID | Term |
|---|---|
| D003015 | Clostridium Infections |
| D003967 | Diarrhea |
| ID | Term |
|---|---|
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077732 | Fidaxomicin |
| C487655 | OPT 80 |
| D014640 | Vancomycin |
| ID | Term |
|---|---|
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D061065 | Polyketides |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D006020 | Glycopeptides |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
| Male |
|
| Canada |
|
|
|
|
|